FDA NDA Approval Letter to Shire PLC for ADHD Medication Intuniv
September 3, 2009 The U.S. Food and Drug Administration approved Intuniv, an extended release formulation of guanfacin as a pediatric treatment for attention deficit/hyperactivity disorder (ADHD). Clinical trials found the medication was better than a placebo at relieving ADHD symptoms for 24 hours. The medication, in dosage strengths of 1 mg, 2 mg, 3 mg, and 4 mg, will be available as of November 2009. Download the Report . . .
